Our content is fact checked by our senior editorial staff to reflect accuracy and ensure our readers get sound information and advice to make the smartest, healthiest choices.
"We came up with a very simple approach, using our unique invention—nanogels that we can direct selectively to different targets, which we call IntelliGels," Thayumanavan explained."They were custom-designed for hepatocyte delivery in the liver." "We realized we needed to deliver this drug selectively to the liver because if it goes to other places, it could cause complications," Thayumanavan said.Notably, the team's trials were only conducted in mice. But"considering 100 million Americans have obesity and related cardiometabolic disorders, we became pretty excited about this work," Thayumanavan said.